BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

...$63 million. Existing investors Column Group and DCVC Bio...
BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

...Myers Squibb Co. (NYSE:BMY).The project first drew the attention of seed investors MPM Capital and DCVC Bio...
...Michael JensenUniversity collaborators: Purdue UniversityCorporate partners: N/ANumber of employees: 38Funds raised: $61 millionInvestors: MPM Capital, DCVC Bio...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...MPM Capital (see “The Dynamics of Dyne”).DCVC closes latest bio fund at $350M DCVC has launched DCVC Bio...
BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

...company experience. An undisclosed investor also co-led the round. Other series D investors included 8VC, DCVC Bio...
...N/A Number of employees: 40 Funds raised: About $300 million Investors: Lightspeed Venture Partners, 8VC, DCVC Bio...
BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

...therapy proposed the offering early that day. Big data investor DCVC aiming for $275M fund DCVC Bio...
...Targets S1PR1 (S1P1; EDG1) - Sphingosin 1-phosphate receptor 1 BioCentury Staff Windtree Therapeutics Inc. Allogene Therapeutics Inc. Adaptimmune Therapeutics plc DCVC Bio KL4...
BioCentury | May 28, 2020
Finance

Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D

...all partnered -- through Phase II testing. New investor OrbiMed Advisors and existing investor DCVC Bio...
BioCentury | Jan 9, 2020
Company News

Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline

...A round. Ionis contributed $10 million in equity to lead the $17 million A-2 round. DCVC Bio...
BioCentury | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

...Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

...AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio...
...of several veteran drug developers with the world’s most advanced AI small molecule discovery engine,” DCVC Bio’s...
BioCentury | Oct 17, 2019
Company News

Plexium debuts with $28M, aims to induce protein degradation by searching all possibilities

...to sort through millions of compounds for those that send E3 ligases to therapeutic targets. DCVC Bio...
Items per page:
1 - 10 of 13
BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

...$63 million. Existing investors Column Group and DCVC Bio...
BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

...Myers Squibb Co. (NYSE:BMY).The project first drew the attention of seed investors MPM Capital and DCVC Bio...
...Michael JensenUniversity collaborators: Purdue UniversityCorporate partners: N/ANumber of employees: 38Funds raised: $61 millionInvestors: MPM Capital, DCVC Bio...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...MPM Capital (see “The Dynamics of Dyne”).DCVC closes latest bio fund at $350M DCVC has launched DCVC Bio...
BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

...company experience. An undisclosed investor also co-led the round. Other series D investors included 8VC, DCVC Bio...
...N/A Number of employees: 40 Funds raised: About $300 million Investors: Lightspeed Venture Partners, 8VC, DCVC Bio...
BioCentury | Jun 3, 2020
Finance

June 2 Financial Quick Takes: follow-ons for Allogene, Adaptimmune, plus DCVC Bio, Windtree and BMS

...therapy proposed the offering early that day. Big data investor DCVC aiming for $275M fund DCVC Bio...
...Targets S1PR1 (S1P1; EDG1) - Sphingosin 1-phosphate receptor 1 BioCentury Staff Windtree Therapeutics Inc. Allogene Therapeutics Inc. Adaptimmune Therapeutics plc DCVC Bio KL4...
BioCentury | May 28, 2020
Finance

Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D

...all partnered -- through Phase II testing. New investor OrbiMed Advisors and existing investor DCVC Bio...
BioCentury | Jan 9, 2020
Company News

Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline

...A round. Ionis contributed $10 million in equity to lead the $17 million A-2 round. DCVC Bio...
BioCentury | Jan 8, 2020
Financial News

Novome raises $33M series A, shoots for the gut with engineered microbes

...Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

...AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio...
...of several veteran drug developers with the world’s most advanced AI small molecule discovery engine,” DCVC Bio’s...
BioCentury | Oct 17, 2019
Company News

Plexium debuts with $28M, aims to induce protein degradation by searching all possibilities

...to sort through millions of compounds for those that send E3 ligases to therapeutic targets. DCVC Bio...
Items per page:
1 - 10 of 13